Iolyx
10 employees on LinkedIn · 1 known investors
Iolyx Therapeutics develops targeted immunomodulatory therapeutics for ocular inflammatory diseases at the intersection of immunology and ophthalmology, addressing conditions affecting both the front of the eye (such as dry eye, ocular allergies, and uveitis) and the back of the eye (such as age-related macular degeneration and diabetic retinopathy). The company aims to create alternatives to steroids and immunosuppressants with improved efficacy, safety, and convenience.
Founders & leadership
Investors · 1
Frequently asked questions
- What does Iolyx do?
- Iolyx Therapeutics develops targeted immunomodulatory therapeutics for ocular inflammatory diseases at the intersection of immunology and ophthalmology, addressing conditions affecting both the front of the eye (such as dry eye, ocular allergies, and uveitis) and the back of the eye (such as age-related macular degeneration and diabetic retinopathy). The company aims to create alternatives to steroids and immunosuppressants with improved efficacy, safety, and convenience.
- Who are Iolyx's investors?
- Iolyx's investors include Frazier Life Sciences.